Test Price
2,800 AED✅ Home Collection Available
ARHGDIA Gene Nephrotic Syndrome Type 8 Genetic Test in Dubai, UAE – NGS Panel for Steroid‑Resistant Nephrotic Syndrome
Executive Summary & Core Metrics
- Definitive Molecular Diagnosis: Targeted NGS analysis of the ARHGDIA gene for steroid‑resistant nephrotic syndrome type 8 (SRNS8).
- Price: 2,800 AED – exclusive of home collection fee.
- Turnaround Time: 3–4 weeks from sample receipt.
- Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily 8 AM – 11 PM.
- Post‑Test Support: Dedicated DHA‑licensed Consultant Medical Geneticist for result interpretation and family counselling.
Test Overview & Methodology
This advanced Next Generation Sequencing (NGS) test interrogates the full coding region and flanking intronic boundaries of the ARHGDIA gene. Pathogenic variants in ARHGDIA cause autosomal recessive nephrotic syndrome type 8, a form of steroid‑resistant nephrotic syndrome (SRNS) that often presents in early childhood and requires precise genetic confirmation for optimal therapeutic management. The assay achieves a diagnostic sensitivity greater than 99% for single‑nucleotide variants and small insertions/deletions.
| Feature | Our NGS Panel | Alternative (Sanger) |
|---|---|---|
| Coverage | Full ARHGDIA gene ± regulatory regions | Hot‑spot exons only |
| Variant Detection | Novel & known pathogenic variants | Known SNPs only |
| Turnaround | 3–4 weeks | 4–6 weeks |
| Clinical Utility | Comprehensive – guides therapy & cascade screening | Limited to known familial mutations |
Physician Insight & Safety Protocols
“As a Consultant Medical Geneticist registered with the Dubai Health Authority, I confirm that comprehensive NGS analysis of the ARHGDIA gene is pivotal for distinguishing steroid‑resistant nephrotic syndrome type 8 from other podocytopathies. A definitive molecular diagnosis empowers tailored immunosuppressive strategies and informs family genetic counselling. Nevertheless, all genetic findings must be evaluated in conjunction with renal biopsy histology and full clinical picture.”
— Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory: Medication Continuity
Do not discontinue prescribed corticosteroids, immunosuppressants, or antihypertensive therapy solely on the basis of a genetic report. Any change in treatment must be supervised by your treating nephrologist to avoid acute nephrotic crisis.
Exclusion Criteria & Urgent Warning
- This test is not validated for acute kidney injury, isolated microalbuminuria, or sub‑nephrotic range proteinuria.
- It does not replace renal biopsy; histology remains essential for morphological classification.
- Raw sequencing data should only be interpreted by a certified genetic counsellor or medical geneticist.
🚨 Seek emergency care if you experience: sudden anasarca, respiratory difficulty, oliguria/anuria, or severe hypertension.
Patient FAQ & Clinical Guidance
1. What is the clinical role of the ARHGDIA gene in nephrotic syndrome?
The ARHGDIA gene encodes a regulator of Rho‑GTPase signalling. Loss‑of‑function mutations lead to podocyte cytoskeletal disruption and steroid‑resistant nephrotic syndrome type 8. Genetic testing confirms the molecular aetiology, enabling targeted therapy (e.g., RAC1 pathway modulators) and cascade screening in at‑risk family members.
2. How is the DNA sample collected, and when will I receive the result?
A DHA‑licensed phlebotomist performs a simple whole‑blood draw or buccal swab at your home between 8 AM and 11 PM daily. The sample is transported via temperature‑controlled cold‑chain to our CAP‑accredited laboratory. A comprehensive NGS interpretive report is delivered within 3 to 4 weeks.
3. Does my UAE health insurance cover this genetic test?
Most UAE insurance plans cover genetic testing for steroid‑resistant nephrotic syndrome once pre‑authorisation is obtained. Our billing team verifies your policy instantly via WhatsApp at +971 54 548 8731 and provides a pre‑approval reference prior to sample collection.
UAE Regulatory & Data Privacy Adherence
- DHA Facility License: 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
- Data Protection Compliance: Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) ensures that all genetic and personal health data is processed lawfully, stored securely, and never shared without explicit consent.
- Health ICT Regulation: Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields governs the electronic handling and sharing of health information.
- Laboratory Accreditation: ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) – certified management system for consistent quality in diagnostic services.
Clinical & Logistical Metadata
| Test Name | ARHGDIA Gene Nephrotic Syndrome Type 8 (SRNS) Genetic Test – NGS Panel |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole Blood (EDTA) or Buccal Swab |
| Methodology Used | Next Generation Sequencing (Illumina® – Full Gene Analysis) |
| ICD-10-CM Code | Q87.8 |
| LOINC Code | 81413-4 |
| DHA Facility License & Laboratory Address | Licence 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians